The effect of simultaneous CD154 and LFA-1 blockade on the survival of allogeneic islet grafts in nonobese diabetic mice

Author(s): Berney T, Pileggi A, Molano RD, Poggioli R, Zahr E, et al.


Background: The rate of success in clinical transplantation of islets of Langerhans has dramatically improved with perspectives of wide-scale applicability for patients with type 1 diabetes. One drawback is the need for lifelong immunosuppression, which is associated with significant side effects. Immunomodulatory strategies devoid of side effects and with tolerogenic potential, such as co-stimulatory blockade, would be a great improvement if successful. In this study, the authors have explored the effect of simultaneous blockade of CD40/CD154 and intercellular adhesion molecule (ICAM)/lymphocyte function-associated antigen (LFA)-1 interactions.

Methods: Spontaneously diabetic nonobese diabetic (NOD) mice underwent transplantation with allogeneic (C57BL/6) islets and were treated with anti-CD154 monoclonal antibody (mAb) (500 microg, three doses), anti-LFA-1 mAb (100 microg, three doses), or a combination of both in the early peritransplant period. In another set of experiments, LFA-1 engagement was impaired by transplanting islets isolated from ICAM-1-knockout (KO) mice.

Results: Untreated animals rejected their grafts within 10 days. LFA-1 blockade alone did not result in improved islet graft survival, whereas CD154 blockade alone increased graft survival to 18 days. Simultaneous blockade of both pathways led to significantly improved islet graft survival to 30 days (ICAM-1-KO islets plus anti-CD154), 35 days (anti-LFA-1 plus anti-CD154), and 44 days (ICAM-1-KO islets plus anti-LFA-1 plus anti-CD154).

Conclusions: These data suggest that a synergistic effect for prolonged graft survival can be obtained by simultaneously targeting CD154 and LFA-1 in the challenging model of islet allotransplantation in NOD mice. The observation of similar results with anti-LFA-1 mAb and with ICAM-1-KO grafts suggests a key role of direct antigen presentation for the activation of LFA-1-driven signaling.

Similar Articles

Costimulation blockade: towards clinical application

Author(s): Weaver TA, Charafeddine AH, Kirk AD

The B7 family revisited

Author(s): Greenwald RJ, Freeman GJ, Sharpe AH

T-cell clonal anergy

Author(s): Schwartz RH, Mueller DL, Jenkins MK, Quill H

Induction of immunologic tolerance for transplantation

Author(s): Rossini AA, Greiner DL, Mordes JP

The role of peripheral T-cell deletion in transplantation tolerance

Author(s): Wells AD, Li XC, Strom TB, Turka LA

Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells

Author(s): Bour-Jordan H, Salomon BL, Thompson HL, Szot GL, Bernhard MR, et al.

The BB/Wor rat and the balance hypothesis of autoimmunity

Author(s): Mordes JP, Bortell R, Doukas J, Rigby M, Whalen B, et al.

The pathogenesis of autoimmune diabetes mellitus

Author(s): Rossini AA, Mordes JP, Greiner DL

Induction of immunological tolerance to islet allografts

Author(s): Rossini AA, Parker DC, Phillips NE, Durie FH, Noelle RJ, et al.

CD28/B7 regulation of autoimmune diabetes

Author(s): Herold KG, Lenschow DJ, Bluestone JA

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

Author(s): Larsen CP, Elwood ET, Alexander DZ, Ritchie SC, Hendrix R, et al.

Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates

Author(s): Adams AB, Shirasugi N, Durham MM, Strobert E, Anderson D, et al.

CD28/B7 regulation of anti-CD3-mediated immunosuppression in vivo

Author(s): Tang Q, Smith JA, Szot GL, Zhou P, Alegre ML, et al.

What's next in the pipeline

Author(s): Vincenti F, Kirk AD

Prolonged islet allograft survival in diabetic NOD mice by targeting CD45RB and CD154

Author(s): Molano RD, Pileggi A, Berney T, Poggioli R, Zahr E, et al.

Islet cell transplantation tolerance

Author(s): Rossini AA, Mordes JP, Greiner DL, Stoff JS

Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

Author(s): Kawai T, Andrews D, Colvin RB, Sachs DH, Cosimi AB

Signaling through CD28 and CTLA-4 controls two distinct forms of T cell anergy

Author(s): Wells AD, Walsh MC, Bluestone JA, Turka LA

Differentiation of regulatory Foxp3+ T cells in the thymic cortex

Author(s): Liston A, Nutsch KM, Farr AG, Lund JM, Rasmussen JP, et al.

CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes

Author(s): Lenschow DJ, Herold KC, Rhee L, Patel B, Koons A, et al.

In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes

Author(s): Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, et al.

Expansion of human regulatory T-cells from patients with type 1 diabetes

Author(s): Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, et al.

Recognition of the peripheral self by naturally arising CD25+ CD4+ T cell receptors

Author(s): Hsieh CS, Liang Y, Tyznik AJ, Self SG, Liggitt D, et al.

Insulin dependent diabetes mellitus hypothesis of autoimmunity

Author(s): Rossini AA, Handler ES, Greiner DL, Mordes JP